Wells Fargo analyst Derek Archila initiated coverage of Alumis (ALMS) with an Overweight rating and $17 price target The firm says the bull case on the shares centers around A-005 in multiple sclerosis and ESK-001’s opportunity in systemic lupus erythematosus.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMS:
- Alumis Inc.: Buy Rating Affirmed Amid Promising ESK-001 Developments and Strong Financial Projections
- Alumis completes patient enrollment in global LUMUS Phase 2b trial of ESK-001
- Alumis promotes Sanam Pangali to chief legal officer
- Alumis files $400M mixed securities shelf
- Largest borrow rate increases among liquid names